Key facts
- Notable investors include Cites Startups.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Amnova Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Amnova Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amnova Biotech
Developer of regenerative injectable biomimetic hydrogels designed to repair cardiac tissue following myocardial infarction. The therapeutic product utilizes a recombinant synthetic composition inspired by human birth tissues to deliver bioactive proteins via localized intramyocardial injection, enabling healthcare providers to promote angiogenesis, reduce fibrosis, and activate endogenous cardiac repair in patients suffering from heart failure.
- Sector
- Healthcare
- HQ
- Sunchales, Argentina
- Website
- amnova-biotech.com/
- Ownership
- Privately Held (backing)
Amnova Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amnova Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amnova Biotech in its N-PORT filings yet. We sweep new filings monthly.